MX2017015311A - Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. - Google Patents
Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.Info
- Publication number
- MX2017015311A MX2017015311A MX2017015311A MX2017015311A MX2017015311A MX 2017015311 A MX2017015311 A MX 2017015311A MX 2017015311 A MX2017015311 A MX 2017015311A MX 2017015311 A MX2017015311 A MX 2017015311A MX 2017015311 A MX2017015311 A MX 2017015311A
- Authority
- MX
- Mexico
- Prior art keywords
- cpg
- antibody
- combination
- treating cancer
- type oligonucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente descripción describe terapias de combinación que comprenden un anticuerpo anti-IL-10 o un fragmento de unión al antígeno del mismo y un oligonucleótido tipo CpG-C, y el uso de las terapias de combinación para el tratamiento de cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562168470P | 2015-05-29 | 2015-05-29 | |
US201562169321P | 2015-06-01 | 2015-06-01 | |
PCT/US2016/034285 WO2016196178A1 (en) | 2015-05-29 | 2016-05-26 | Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017015311A true MX2017015311A (es) | 2018-06-19 |
Family
ID=57442233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015311A MX2017015311A (es) | 2015-05-29 | 2016-05-26 | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20180161427A1 (es) |
EP (1) | EP3302554A4 (es) |
JP (1) | JP2018516252A (es) |
KR (1) | KR20180014010A (es) |
CN (1) | CN107949399A (es) |
AU (1) | AU2016271023A1 (es) |
BR (1) | BR112017025533A2 (es) |
CA (1) | CA2986232A1 (es) |
MA (1) | MA44700A (es) |
MX (1) | MX2017015311A (es) |
RU (1) | RU2017145559A (es) |
WO (1) | WO2016196178A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
DK3302502T3 (da) * | 2015-05-29 | 2019-10-28 | Dynavax Tech Corp | Intrapulmonal administration af polynukleotid-agonister af toll-lignende receptor-9 til behandling af lungecancer |
AU2016271018A1 (en) | 2015-05-29 | 2017-11-30 | Dynavax Technologies Corporation | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
ES2381309T3 (es) * | 2002-12-23 | 2012-05-25 | Dynavax Technologies Corporation | Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos |
AR046833A1 (es) * | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
JP2008531481A (ja) * | 2005-02-08 | 2008-08-14 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | 癌の治療のための、mda−7を含む組成物および方法 |
EP2004691A1 (en) * | 2006-03-22 | 2008-12-24 | Apogenix GmbH | Antibody specific for human il-4 for the treament of cancer |
JP2009016596A (ja) * | 2007-07-05 | 2009-01-22 | Elpida Memory Inc | 半導体装置及び半導体装置の製造方法 |
EP2190440A1 (en) * | 2007-08-13 | 2010-06-02 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
-
2016
- 2016-05-26 EP EP16804055.8A patent/EP3302554A4/en not_active Withdrawn
- 2016-05-26 BR BR112017025533A patent/BR112017025533A2/pt not_active Application Discontinuation
- 2016-05-26 US US15/577,377 patent/US20180161427A1/en not_active Abandoned
- 2016-05-26 RU RU2017145559A patent/RU2017145559A/ru not_active Application Discontinuation
- 2016-05-26 WO PCT/US2016/034285 patent/WO2016196178A1/en active Application Filing
- 2016-05-26 AU AU2016271023A patent/AU2016271023A1/en not_active Abandoned
- 2016-05-26 JP JP2017561618A patent/JP2018516252A/ja active Pending
- 2016-05-26 KR KR1020177037186A patent/KR20180014010A/ko unknown
- 2016-05-26 CA CA2986232A patent/CA2986232A1/en not_active Abandoned
- 2016-05-26 MX MX2017015311A patent/MX2017015311A/es unknown
- 2016-05-26 CN CN201680043447.4A patent/CN107949399A/zh active Pending
- 2016-05-26 MA MA044700A patent/MA44700A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP3302554A1 (en) | 2018-04-11 |
KR20180014010A (ko) | 2018-02-07 |
RU2017145559A (ru) | 2019-07-03 |
WO2016196178A1 (en) | 2016-12-08 |
CA2986232A1 (en) | 2016-12-08 |
AU2016271023A1 (en) | 2017-11-30 |
US20180161427A1 (en) | 2018-06-14 |
MA44700A (fr) | 2019-02-27 |
JP2018516252A (ja) | 2018-06-21 |
CN107949399A (zh) | 2018-04-20 |
BR112017025533A2 (pt) | 2018-08-07 |
EP3302554A4 (en) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL270720A (en) | Combination of treatments for cancer treatment | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
MX2017015311A (es) | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. | |
MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2018008995A (es) | Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer. | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
MX2017001587A (es) | Terapia de combinacion para tratar un paramixovirus. | |
MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
MX2019004500A (es) | Terapia de combinación para la inhibición de componente de complemeto (c3). | |
MX2020003770A (es) | Terapias de combinacion para tratar cancer. | |
EP3621592A4 (en) | POLYTHERAPIES FOR CANCER TREATMENT | |
EA201991818A1 (ru) | Лечение рака | |
MA40364A (fr) | Polythérapie pour le traitement du cancer | |
MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
MX2020006297A (es) | Variantes de cd19. | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
MX2016009597A (es) | Terapias para el influenzavirus a subtipo h7n9. | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
HK1243439A1 (zh) | Pcsk9抗體、其抗原結合片段及其醫藥用途 | |
EP3283529A4 (en) | Agents, systems and methods for treating cancer | |
IL278921A (en) | Combined treatments for cancer |